Mirum Pharmaceuticals reported a robust second quarter, with total revenues reaching $128 million, marking a 64% year-over-year increase. This growth was primarily driven by strong sales of Livmarli, which generated $57 million in the U.S. and $31 million internationally, benefiting from rising patient volumes in Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille syndrome. The company has raised its full-year revenue guidance to between $490 million and $510 million, signaling confidence in continued commercial momentum.

The strong performance reflects not only the successful expansion of Livmarli’s market presence but also the strategic advancements in Mirum’s clinical pipeline. The company is on track to complete enrollment in key studies, including the VISTAS Phase IIb trial for Primary Sclerosing Cholangitis (PSC) and a Phase II study for Fragile X syndrome, which could further enhance its product offerings and revenue potential.

For market professionals, Mirum’s ability to maintain positive cash flow and improve operating margins while expanding its product pipeline is a significant indicator of its financial health and growth trajectory. The ongoing demand for Livmarli and the potential for new indications could position Mirum as a key player in the rare disease market.

Source: fool.com